# Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program

> **NCT06253637** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 31 (estimated)

## Conditions studied

- T-Lymphocytic Leukemia, Acute

## Interventions

- **DRUG:** Daratumumab plus chemotherapy according to the national treatment program

## Key facts

- **NCT ID:** NCT06253637
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-17
- **Primary completion:** 2029-10
- **Final completion:** 2029-10
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06253637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06253637, "Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06253637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*